Melanoma Research Today is a free monthly online journal that collates and summarizes the latest research about Melanoma, including details on identification, causes, prevention, treatment.

Volume 2 (2005), Issue 4 (April)

1. Liposome-encapsulated prednisolone phosphate inhibits growth of established tumors in mice.
   Neoplasia, 7(2): 118-27. [Abstract] [Full-text]
2. Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand.
   Blood, 105(8): 3206-13. [Abstract] [Full-text]
3. Endogenous retrovirus expression is required for murine melanoma tumor growth in vivo.
   Cancer Res, 65(7): 2588-91. [Abstract] [Full-text]
4. Ultrasonographic tissue characteristics of mushroom-shaped uveal melanoma.
   Curr Eye Res, 30(3): 171-7. [Abstract] [Full-text]
5. Prolidase, a potential enzyme target for melanoma: design of proline-containing dipeptide-like prodrugs.
   Mol Pharm, 2(1): 37-46. [Abstract] [Full-text]
6. Therapeutic effect of gene-therapy in combination with local X-irradiation in a mouse malignant melanoma model.
   Biochem Biophys Res Commun, 330(3): 975-81. [Abstract] [Full-text]
7. Intronic sequence variants of the CDKN2A gene in melanoma pedigrees.
   Genes Chromosomes Cancer, 43(2): 128-36. [Abstract] [Full-text]
8. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells.
   Eur J Immunol, 35(4): 1066-75. [Abstract] [Full-text]
9. Detection of the BRAF V600E mutation in melanocytic lesions using the ligase detection reaction.
   J Cutan Pathol, 32(5): 334-9. [Abstract] [Full-text]
10. Nucleolar organizer region staining patterns in paraffin-embedded tissue cells from human skin cancers.
    J Cutan Pathol, 32(5): 323-8. [Abstract] [Full-text]
11. Automated melanoma detection with a novel multispectral imaging system: results of a prospective study.
    Phys Med Biol, 50(8): 1675-87. [Abstract] [Full-text]
12. Melanoma.
    Clin Plast Surg, 32(2): 249-59. [Abstract] [Full-text]
13. A secreted form of P-cadherin is expressed in malignant melanoma.
    Exp Cell Res, 305(2): 418-26. [Abstract] [Full-text]
14. Melanoma cells express elevated levels of phosphorylated histone H2AX foci.
    J Invest Dermatol, 124(4): 807-17. [Abstract] [Full-text]
15. Wide local excision or abdominoperineal resection as the initial treatment for anorectal melanoma?
    Am J Surg, 189(4): 446-9. [Abstract] [Full-text]
16. No Evidence for BRAF as a melanoma/nevus susceptibility gene.
    Cancer Epidemiol Biomarkers Prev, 14(4): 913-8. [Abstract] [Full-text]
17. Site specific therapy: an integrative approach to treating melanoma.
    Med Hypotheses, 64(6): 1097-9. [Abstract] [Full-text]
18. Desmoplastic melanoma: a pathologically and clinically distinct form of cutaneous melanoma.
    Ann Surg Oncol, 12(3): 207-13. [Abstract] [Full-text]
19. Popliteal lymph node dissection.
    Ann Surg Oncol, 12(2): 189-93. [Abstract] [Full-text]
20. Ultrasound examination of sentinel nodes in the initial assessment of patients with primary cutaneous melanoma.
    Ann Surg Oncol, 12(1): 18-23. [Abstract] [Full-text]
21. Toxicity of fatty acids on murine and human melanoma cell lines.
    Toxicol In Vitro, 19(4): 553-60. [Abstract] [Full-text]
22. Clinicopathologic significance of dysadherin expression in cutaneous malignant melanoma: immunohistochemical analysis of 115 patients.
    Cancer, 103(8): 1693-700. [Abstract] [Full-text]
23. Differences in phenotype and function between spontaneously occurring melan-A-, tyrosinase- and influenza matrix peptide-specific CTL in HLA-A*0201 melanoma patients.
    Int J Cancer, 115(3): 450-5. [Abstract] [Full-text]
24. Selective sensitivity to wasabi-derived 6-(methylsulfinyl)hexyl isothiocyanate of human breast cancer and melanoma cell lines studied in vitro.
    Cancer Detect Prev, 29(2): 155-60. [Abstract] [Full-text]
25. Tumor-induced suppression of interferon-gamma production and enhancement of interleukin-10 production by natural killer (NK) cells: paralleled to CD4+ T cells.
    Mol Immunol, 42(9): 1023-31. [Abstract] [Full-text]
26. Imaging of melanoma using 64Cu- and 86Y-DOTA-ReCCMSH(Arg11), a cyclized peptide analogue of alpha-MSH.
    J Med Chem, 48(8): 2985-92. [Abstract] [Full-text]
27. Exon 15 BRAF mutations are uncommon in canine oral malignant melanomas.
    Mamm Genome, 16(3): 211-7. [Abstract] [Full-text]
28. Release of biologically functional interferon-alpha from a nanochannel delivery system.
    Biomed Microdevices, 7(1): 71-9. [Abstract] [Full-text]
29. Constitutive expression and costimulatory function of LIGHT/TNFSF14 on human melanoma cells and melanoma-derived microvesicles.
    Cancer Res, 65(8): 3428-36. [Abstract] [Full-text]
30. C-C chemokine receptor 5 on stromal cells promotes pulmonary metastasis.
    Cancer Res, 65(8): 3374-9. [Abstract] [Full-text]
31. Risk factors and individual probabilities of melanoma for whites.
    J Clin Oncol, 23(12): 2669-75. [Abstract] [Full-text]
32. Treatment of lentigo maligna (melanoma in situ) with the immune response modifier imiquimod.
    Arch Dermatol, 141(4): 510-4. [Abstract] [Full-text]
33. Association of UV index, latitude, and melanoma incidence in nonwhite populations--US Surveillance, Epidemiology, and End Results (SEER) Program, 1992 to 2001.
    Arch Dermatol, 141(4): 477-81. [Abstract] [Full-text]
34. Detection of lymphatic invasion in primary melanoma with monoclonal antibody D2-40: a new selective immunohistochemical marker of lymphatic endothelium.
    Arch Dermatol, 141(4): 440-4. [Abstract] [Full-text]
35. First prospective study of the recognition process of melanoma in dermatological practice.
    Arch Dermatol, 141(4): 434-8. [Abstract] [Full-text]
36. Phase II trial of karenitecin in patients with malignant melanoma: clinical and translational study.
    Clin Cancer Res, 11(8): 3009-16. [Abstract] [Full-text]
37. Biallelic deletions in INK4 in cutaneous melanoma are common and associated with decreased survival.
    Clin Cancer Res, 11(8): 2991-7. [Abstract] [Full-text]
38. Melanoma treatment update.
    Dermatol Clin, 23(2): 323-33. [Abstract] [Full-text]
39. Beneficial therapeutic effects with different particulate structures of murine polyomavirus VP1-coat protein carrying self or non-self CD8 T cell epitopes against murine melanoma.
    Cancer Immunol Immunother, 54(6): 611-22. [Abstract] [Full-text]
40. Melanoma genetics and the development of rational therapeutics.
    J Clin Invest, 115(4): 813-24. [Abstract] [Full-text]
41. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.
    Br J Dermatol, 152(4): 690-6. [Abstract] [Full-text]
42. Circulating vascular endothelial growth factor in cutaneous malignant melanoma.
    Br J Dermatol, 152(4): 685-9. [Abstract] [Full-text]
43. Dysplastic naevus vs. in situ melanoma: digital dermoscopy analysis.
    Br J Dermatol, 152(4): 679-84. [Abstract] [Full-text]
44. Desmoplastic malignant melanoma: a systematic review.
    Br J Dermatol, 152(4): 673-8. [Abstract] [Full-text]
45. Experience with mucosal melanoma of the nose and paranasal sinuses.
    ANZ J Surg, 75(4): 192-7. [Abstract] [Full-text]
46. Management of nevi in transplant patients.
    Dermatol Ther, 18(1): 34-43. [Abstract] [Full-text]
47. Predictors of quality of life in newly diagnosed melanoma and breast cancer patients.
    Ann Oncol, 16(5): 805-16. [Abstract] [Full-text]
48. Flexible, actin-based ridges colocalise with the beta1 integrin on the surface of melanoma cells.
    Br J Cancer, 92(8): 1499-505. [Abstract] [Full-text]
49. Lack of clinical efficacy of imatinib in metastatic melanoma.
    Br J Cancer, 92(8): 1398-405. [Abstract] [Full-text]
50. Different manifestations of malignant melanoma in the breast: a report of 12 cases and a review of the literature.
    Jpn J Clin Oncol, 35(4): 202-6. [Abstract] [Full-text]
51. Total reconstruction of the upper lip after resection of a malignant melanoma.
    Scand J Plast Reconstr Surg Hand Surg, 39(1): 45-7. [Abstract] [Full-text]
52. Histamine elevates the expression of Ets-1, a protooncogen in human melanoma cell lines through H2 receptor.
    FEBS Lett, 579(11): 2475-9. [Abstract] [Full-text]
53. Whole-body bioluminescent imaging of human uveal melanoma in a new mouse model of local tumor growth and metastasis.
    Invest Ophthalmol Vis Sci, 46(5): 1581-7. [Abstract] [Full-text]
54. Functional analysis of the p53 pathway in response to ionizing radiation in uveal melanoma.
    Invest Ophthalmol Vis Sci, 46(5): 1561-4. [Abstract] [Full-text]
55. Significance of serum S-100B in melanoma patients before and after sentinel node biopsy.
    J Surg Oncol, 90(2): 66-9; discussion 69-70. [Abstract] [Full-text]
56. Osteopontin expression correlates with melanoma invasion.
    J Invest Dermatol, 124(5): 1044-52. [Abstract] [Full-text]
57. Selective monomorphic and polymorphic HLA class I antigenic determinant loss in surgically removed melanoma lesions.
    Tissue Antigens, 65(5): 419-28. [Abstract] [Full-text]
58. The gene expression signatures of melanoma progression.
    Proc Natl Acad Sci U S A, 102(17): 6092-7. [Abstract] [Full-text]
59. Improvement of paclitaxel therapeutic index by derivatization and association to a cholesterol-rich microemulsion: in vitro and in vivo studies.
    Cancer Chemother Pharmacol, 55(6): 565-76. [Abstract] [Full-text]
60. Differential expression of tissue inhibitor of matrix metalloproteinases 3 in uveal melanoma.
    Ophthalmic Res, 37(1): 23-8. [Abstract] [Full-text]
61. Analysis of Bcl-2 protein expression in choroidal melanomas.
    J Clin Pathol, 58(5): 486-9. [Abstract] [Full-text]
62. Melanocytic dysplastic naevi occupy the middle ground between benign melanocytic naevi and cutaneous malignant melanomas: emerging clues.
    J Clin Pathol, 58(5): 453-6. [Abstract] [Full-text]
63. Case-control study to identify melanoma risk factors in the Belgian population: the significance of clinical examination.
    J Eur Acad Dermatol Venereol, 19(3): 332-9. [Abstract] [Full-text]
64. Randomized trial of hyperthermia and radiation for superficial tumors.
    J Clin Oncol, 23(13): 3079-85. [Abstract] [Full-text]
65. Role of the CDKN2A locus in patients with multiple primary melanomas.
    J Clin Oncol, 23(13): 3043-51. [Abstract] [Full-text]
66. Malignant melanoma and filariasis: a coexistence or an association?
    Int J Low Extrem Wounds, 4(1): 60-4. [Abstract] [Full-text]

© 2004-2008 Melanoma Research Today. All Rights Reserved.